

## REMARKS

The claims have been amended to simplify prosecution and clarify the relationship of the present application to the disclosure of PCT publication WO 00/20590 assigned to Incyte Pharmaceuticals, Inc. The PHOR-1 polypeptide described in that application differs by one amino acid from that set forth herein as SEQ. ID. NO: 2. In the Incyte application, position 104 contains methionine; in SEQ. ID. NO: 2 position 104 is isoleucine.

Thus, claims 44, 47-51 and 54-58 are generic to the subject matter set forth in the above-referenced PCT application and the present application.

Support for the amended claims is found in claims 1-28 originally pending, especially claims 2, 5-8, 11, 13-14, 16 and 20, and throughout the specification. Support for conservative substitutions is found on page 27. No new matter has been added and entry of the amendment is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 511582002410.

Respectfully submitted,

Dated: August 16, 2002

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125